Wednesday, 14 October 2026European Markets

QRF And HOME INVEST BE. Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(VIANEWS) - QRF (QRF.BR) is among this list of stock assets with the highest dividend rate and return on equity on the Real Estate sector.

Financial Asset Price Forward Dividend Yield Return on Equity
QRF (QRF.BR) €10.70 7.27% 9.24%
HOME INVEST BE. (HOMI.BR) €19.14 5.87% 14.53%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. QRF (QRF.BR)

7.27% Forward Dividend Yield and 9.24% Return On Equity

Qrf Comm. VA is a publicly owned real estate investment trust. It invests in the real estate markets of Belgium. The firm specializes in retail properties. Qrf Comm. VA was founded in September 3, 2013 and is based in Belgium.

Earnings Per Share

As for profitability, QRF has a trailing twelve months EPS of €1.44.

PE Ratio

QRF has a trailing twelve months price to earnings ratio of 7.43. Meaning, the purchaser of the share is investing €7.43 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.24%.

More news about QRF.

2. HOME INVEST BE. (HOMI.BR)

5.87% Forward Dividend Yield and 14.53% Return On Equity

Home Invest Belgium S.A. operates as a real estate investment company in Belgium. It primarily invests in residential properties. As of December 31, 2008, the company's real estate portfolio consisted of 992 rental units with a total rentable space of approximately 111,091 square meters. The company was formerly known as Home Invest and changed its name to Home Invest Belgium S.A. in May 1999. Home Invest Belgium S.A. was founded in 1980 and is based in Brussels, Belgium.

Earnings Per Share

As for profitability, HOME INVEST BE. has a trailing twelve months EPS of €3.22.

PE Ratio

HOME INVEST BE. has a trailing twelve months price to earnings ratio of 5.94. Meaning, the purchaser of the share is investing €5.94 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.53%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HOME INVEST BE.'s stock is considered to be oversold (<=20).

Yearly Top and Bottom Value

HOME INVEST BE.'s stock is valued at €19.14 at 12:30 EST, under its 52-week high of €19.78 and way above its 52-week low of €13.20.

More news about HOME INVEST BE..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com